Hot Topics: Clinical Questions in Schizophrenia – Question II
Dr. Christoph U. Correll will address current and relevant clinical questions relating to schizophrenia. These questions and Dr. Correll’s response will be recorded and released as short videos.
The use of Long Acting Injectables (LAIs) is included less often overall in the available clinical practice guidelines and less still regarding treatment of first episode schizophrenia patients. Are there advantages to treating a first episode schizophrenia patient with a LAI?
Christoph Correll, MD
Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.
Christoph Correll is a paid consultant for Otsuka Pharmaceutical Development Commercialization, Inc. (OPDC)
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
Related Resources
Hot Topics: Clinical Questions in Schizophrenia – Question IV
Interview
Hot Topics: Clinical Questions in Schizophrenia – Question III
Interview
Hot Topics: Clinical Questions in Schizophrenia – Question I
Interview-
Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)
In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.